GvHD Hub @gvhd_hub tweet - Learn more about the treatment options for ruxolitinib-refractory acute #GvHD with our expert interview, featuring Mohamad Mohty. Watch here: https://t.co/syxbvwxDV4 #GvHD #MedEd #GvHDsm https://t.co/PcQmWZcC4E

GvHD Hub

@gvhd_hub

7 days

Learn more about the treatment options for ruxolitinib-refractory acute #GvHD with our expert interview, featuring Mohamad Mohty. Watch here: https://t.co/syxbvwxDV4 #GvHD #MedEd #GvHDsm

Replies

GvHD Hub

@gvhd_hub

3 hours

CONGRESS | #ASH25 | POSTER Robert Zeiser presents an interim safety analysis of a phase II study investigating axatilimab combined with ruxolitinib in patients with newly diagnosed chronic GvHD (N = 43). 32 patients experienced TEAEs and 5 patients experienced Grade ≥3 TEAEs.